Comparison of gallium-68 somatostatin receptor and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography in the diagnosis of neuroendocrine tumours: A systematic review and meta-analysis.
Xue Liu, Ning Li, Tao Jiang, Huaiwei Xu, Qilian Ran, Zhen Shu, Jiang Wu, Youcheng Li, Shiliang Zhou, Bao Zhang
Abstract
OBJECTIVE: F-FDG) PET in patients with neuroendocrine tumours (NET) and whether the two imaging modalities can be mutually substituted in clinical work. METHODS: F-FDG PET in patients or lesions with NET. RESULTS: F-FDG PET/CT were 0.378 (0.319-0.440), 0.554 (0.492-0.615) and 0.712 (0.633-0.783) in the G1, G2 and G3 groups based on patients with NET, respectively. CONCLUSION: F-FDG PET modalities are complementary rather than substitutive in clinical practice.
Topics & Concepts
MedicineSomatostatin receptorPositron emission tomographySomatostatin AnalogueNuclear medicineMeta-analysisSomatostatinNeuroendocrine tumorsPathologyRadiologyInternal medicineOctreotideNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments